人类免疫缺陷病毒（HIV）感染及免疫缺陷对6型或11型人乳头瘤病毒感染和尖锐湿疣的影响。

The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts.

作者信息

Silverberg Michael J, Ahdieh Linda, Munoz Alvaro, Anastos Kathryn, Burk Robert D, Cu-Uvin Susan, Duerr Ann, Greenblatt Ruth M, Klein Robert S, Massad Stewart, Minkoff Howard, Muderspach Laila, Palefsky Joel, Piessens Eva, Schuman Paula, Watts Heather, Shah Keerti V

机构信息

Johns Hopkins School of Public Health, Baltimore, Maryland 21205, USA.

出版信息

Sex Transm Dis. 2002 Aug;29(8):427-35. doi: 10.1097/00007435-200208000-00001.

DOI:10.1097/00007435-200208000-00001

PMID:12172526

Abstract

BACKGROUND

HIV infection and associated immunodeficiency are known to alter the course of human papillomavirus (HPV) infections and of associated diseases.

GOAL

This study investigated the association between HIV and HPV and genital warts.

STUDY DESIGN

HPV testing and physical examinations were performed in two large prospective studies: the Women's Interagency HIV Study (WIHS) and the HIV Epidemiology Research Study (HERS). Statistical methods incorporating dependencies of longitudinal data were used to examine the relationship between HIV and HPV and genital warts.

RESULTS

A total of 1008 HIV-seronegative and 2930 HIV-seropositive women were enrolled in the two studies. The prevalence of HPV 6 or 11 was 5.6 times higher in HIV-seropositive women in the WIHS and 3.6 times higher in the HERS. Genital wart prevalence increased by a factor of 3.2 in the WIHS and 2.7 in the HERS in HIV-seropositive women. In the WIHS, infection with HPV type 6 or 11, in comparison with no HPV infection, was associated with odds of genital wart prevalence of 5.1 (95% CI: 2.9-8.8), 8.8 (95% CI: 6.1-12.8), and 12.8 (95% CI: 8.8-18.8) in HIV-seronegative women, HIV-seropositive women with > or =201 CD4 cells/microl, and HIV-seropositive women with < or =200 CD4 cells/microl, respectively. In the HERS, infection with HPV type 6 or 11 was associated with odds of 2.7 (95% CI: 1.6-4.6), 4.9 (95% CI: 3.2-7.7), and 5.3 (95% CI: 3.3-8.5) in these same groups. Other HPV types showed a similar dose-response relation, but of substantially lower magnitude and statistical significance.

CONCLUSIONS

HIV infection and immunodeficiency synergistically modified the relation between HPV 6 or 11 infection and genital wart prevalence.

摘要

背景

已知HIV感染及相关免疫缺陷会改变人乳头瘤病毒（HPV）感染及相关疾病的病程。

目标

本研究调查了HIV与HPV及尖锐湿疣之间的关联。

研究设计

在两项大型前瞻性研究中进行了HPV检测和体格检查，即女性机构间HIV研究（WIHS）和HIV流行病学研究（HERS）。采用纳入纵向数据依存性的统计方法来检验HIV与HPV及尖锐湿疣之间的关系。

结果

两项研究共纳入了1008名HIV血清学阴性女性和2930名HIV血清学阳性女性。在WIHS中，HIV血清学阳性女性中HPV 6或11的患病率高出5.6倍，在HERS中高出3.6倍。在WIHS中，HIV血清学阳性女性的尖锐湿疣患病率增加了3.2倍，在HERS中增加了2.7倍。在WIHS中，与未感染HPV相比，感染HPV 6或11型在HIV血清学阴性女性、CD4细胞/微升≥201的HIV血清学阳性女性以及CD4细胞/微升≤200的HIV血清学阳性女性中，尖锐湿疣患病率的比值分别为5.1（95%可信区间：2.9 - 8.8）、8.8（95%可信区间：6.1 - 12.8）和12.8（95%可信区间：8.8 - 18.8）。在HERS中，这些相同组中感染HPV 6或11型的比值分别为2.7（95%可信区间：1.6 - 4.6）、4.9（95%可信区间：3.2 - 7.7）和5.3（95%可信区间：3.3 - 8.5）。其他HPV类型显示出类似的剂量反应关系，但幅度和统计学意义明显较低。